[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"degenerative-aortic-valve-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:degenerative-aortic-valve-disease":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100628514",false,"NCT07462624","REpeat Intervention For Failed Surgical BioProsthEtic AorTic Valves (REPEAT)","REpeat Intervention for Failed Surgical BioProsthEtic AorTic Valves (REPEAT): A Multicenter Randomized Trial Comparing Redo Surgical Aortic Valve Replacement to Valve-in-Valve Transcatheter Aortic Valve Replacement","REPEAT","Inclusion Criteria:\n\n* Indication for repeat intervention for failed surgical aortic bioprosthesis due to structural valve deterioration (SVD; prosthesis stenosis and\u002For transprosthetic insufficiency);\n* Low to intermediate surgical risk (i.e., Society of Thoracic Surgeons (STS) predicted risk of mortality of \\\u003C 8%);\n* Age \\> 18 and \\\u003C 75 years;\n* Both rAVR and ViV-TAVR are judged to be reasonable options based on evaluation by the local Heart Team\n\nExclusion Criteria:\n\n* Multiple valvular disease requiring surgical intervention;\n* High-risk coronary anatomy resulting in increased risk of coronary obstruction following ViV-TAVR prosthesis deployment;\n* Complex coronary artery disease requiring revascularization (unprotected left main coronary artery, Syntax score \\> 32) and Heart Team assessment that optimal revascularization cannot be performed;\n* Failing valve with evidence of bacterial endocarditis or evidence of non-structural valve deterioration (e.g., paravalvular leak, thrombosis);\n* Increased post-procedural gradients (mean \\> 20 mmHg) or severe patient-prosthesis mismatch (PPM, indexed effective orifice area \\\u003C 0.65 cm2\u002Fm2) at discharge from index aortic valve replacement (AVR) procedure;\n* Patients who choose to receive a mechanical AVR.","ALL","18 Years","75 Years",{"count":20,"type":21},890,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overall hypothesis is that redo aortic valve replacement (rAVR) is superior to valve-invalve transcatheter aortic valve replacement (ViV-TAVR) for the composite endpoint of freedom from all-cause mortality, all-cause stroke, myocardial infarction, and rehospitalization for heart failure or aortic valve re-intervention at 5 years.",[27],"Degenerative Aortic Valve Disease","RECRUITING","2026-03-05",{"date":31,"type":32},"2026-03-10","ACTUAL",{"date":34,"type":32},"2025-11-10",{"date":36,"type":21},"2033-09-30",{"name":38,"class":39},"Heart Center Leipzig - University Hospital","OTHER",""]